» Articles » PMID: 29851136

Gene Expression Dynamics Following Mithramycin Treatment: A Possible Model for Post-chemotherapy Cognitive Impairment

Overview
Specialties Pharmacology
Physiology
Date 2018 Jun 1
PMID 29851136
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Chemotherapy-induced cognitive changes is a major burden on a substantial number of cancer survivors. The mechanism of this sequel is unknown. In this study, we followed long-term effects of early in life mithramycin (MTR) treatment on behaviour and on the normal course of alterations of gene expression in brain. Between post-natal days (PND) 7 and 10, male rats were divided into 2 groups, 1 receiving MTR (0.1 mg/kg s.c. per day) and the other receiving saline. At PND11, frontal cortex tissue samples were dissected from 4 rats from each group. At PND 65 the remaining rats underwent behavioural tests after which all the rats were decapitated and their prefrontal cortex incised. Rats treated transiently with MTR early in life, showed impairments in spatial working memory and anxious-like behaviour in adulthood. The immediate molecular effect of MTR was expressed in a limited number of altered genes of different unconnected trajectories, which were simultaneously distorted by the drug. In contrast, 3 months later we observed a change in the expression of more than 1000 genes that converged into specific cellular processes. Time-dependent gene expression dynamics of several genes was significantly different between treated and untreated rats. The differences in the total number of altered genes and in gene expression trends, immediately and long after MTR treatment cessation, suggest the evolution of a new cellular homeostatic set point, which can lead to behavioural abnormalities following chemotherapy treatment.

Citing Articles

Chemobrain as a Product of Growing Success in Chemotherapy - Focus on Glia as both a Victim and a Cure.

Walczak P, Janowski M Neuropsychiatry (London). 2019; 9(1):2207-2216.

PMID: 31316584 PMC: 6635604. DOI: 10.4172/Neuropsychiatry.1000565.